Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935573 | 0.94 | MEN1 (0.43) | TYRALDH2ALDH3A1ALDH1A1KDM4E | |
| SCHEMBL2932666 | 0.94 | MEN1 (0.43) | TYRALDH2ALDH3A1ALDH1A1KDM4E | |
| SCHEMBL2934063 | 0.86 | ALDH2 (0.43) | ALDH2ALDH3A1ALDH1A1KDM4EGAA | |
| SCHEMBL11791192 | 0.76 | ALDH2 (0.46) | ALDH2ALDH3A1ALDH1A1KDM4EMAOB | |
| SCHEMBL2936330 | 0.75 | CNR2 (0.38) | ALDH2ALDH3A1CNR2CNR1 | |
| SCHEMBL14282559 | 0.74 | SKP2 (0.38) | ALDH2ALDH3A1ALDH1A1MAPK1HTT | |
| SCHEMBL13389081 | 0.73 | ALDH2 (0.53) | ALDH2ALDH3A1ALDH1A1KDM4EGAA | |
| SCHEMBL6832877 | 0.72 | ALDH2 (0.51) | ALDH2ALDH3A1MAOBTSHR | |
| SCHEMBL28794241 | 0.72 | TYR (0.36) | TYRALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL12640663 | 0.72 | TYR (0.50) | TYRALDH1A1KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-2229169-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009089880-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009089880-A1 | PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | RCC1, RB1, RCC2 | TYR 60/4885ALDH2 3443/4885ALDH3A1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.